Integration of CAR T-Cell Therapy Into the Management of Leukemia, Lymphoma, and Multiple Myeloma
- Review of available efficacy/safety data with approved and investigational CAR T-cell therapies
Identifying and Managing CAR T-Cell–Mediated Toxicities
- Proactive methods to mitigate and manage acute and longer-term adverse events associated with CAR T-cell therapies
Education Considerations for the Multidisciplinary Team Along the CAR T-Cell Journey
- Treatment phases and key education points for the multidisciplinary team
- Successful patient and caregiver strategies (eg, folders created by nurse coordinators and provided to patients at consult, specialized discharge information, and more)
Audience Question and Answer Session
Date / Time
Caron A. Jacobson, MD
Medical Director, Immune Effector Cell Therapy Program
Assistant Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Alix Beaupierre, BSN, RN, OCN
Transplant and Cellular Therapy Nurse Coordinator
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Kathleen McDermott, RN, BSN, OCN, BMTCN
Immune Effector Cell (IEC) Program Nurse Navigator
Dana-Farber Cancer Institute
The goal of this activity is to improve the knowledge, competence, and performance of oncology nurses, nurse practitioners, and clinical nurse specialists in treating patients with leukemia, lymphoma, or multiple myeloma and key elements for education along the treatment journey with CAR T-cell therapy, including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers.
This program is intended for oncology nurses, nurse practitioners, and clinical nurse specialists who care for patients with leukemia, lymphoma, or multiple myeloma.
- Apply the latest safety and efficacy data for currently approved and emerging CAR T-cell therapy in clinical decision-making for the treatment of leukemia, lymphoma, and multiple myeloma
- Discuss key education elements for CAR T-cell therapy including considerations for each stage of therapy and specific recommendations for care teams, patients, and caregivers
- Based on the current best evidence, implement strategies for managing toxicities associated with CAR T-cell therapy
- Recall ongoing clinical trials evaluating CAR T-cell therapy for the treatment of leukemia, lymphoma, and multiple myeloma to aid in the referral of appropriate patients
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.